Tamtam Try Tamtam free
Kerry logo

Kerry account plan

Global leader food solutions

At a glance

Kerry Group is an Irish B2B taste and nutrition ingredients company for food, beverage and pharma: €6,758m FY2025 revenue, 19,000+ employees.

Kerry Group is a B2B taste and nutrition ingredients company that co-creates products with food, beverage and pharma customers in retail and foodservice, using taste technologies (natural extracts, Tastesense™ salt and sugar reduction, flavours) and biotechnology (fermentation, enzymes, probiotics, proteins). Since selling Kerry Dairy Ireland at the end of 2024 it describes itself as a pure-play taste and nutrition company, sizing its addressable market at c. €85bn. FY2025 revenue from continuing operations was €6,758m (-2.5% reported, volume +3.0%), EBITDA €1,208m at a 17.9% margin, and free cash flow €643m. It has 19,000+ employees and 119 manufacturing facilities in 34 countries. Edmond Scanlon has been CEO since October 2017.

Business units

Strategic priorities

2030 financial targets
Announced in July 2026: volume growth of 3-5% on average over 2027-2030 assuming flat end markets, EBITDA margin of 20-21% by 2030, HSD+ constant currency EPS growth, 85%+ cash conversion and 12-13% ROACE by 2030.
Accelerate 2.0 efficiency programme
Runs until 2028, covering footprint optimisation in North America and Europe and digital excellence in manufacturing, commercial enablement and global business service centres; it is the primary driver of margin expansion in FY 2026 and FY 2027.
Renovation, foodservice and emerging markets
Renovation is around 40% of the pipeline and more than half in North America; foodservice volume grew 5.0% and emerging markets 4.9% in the first nine months of 2026.
Biotechnology innovation
Kerry is accelerating biotechnology R&D in next-generation modulation, biotransformation to replace additives and natural preservation; R&D spend is set to rise from 4%-5% to 5%-6% of revenue.
Digital and AI at scale
After piloting, Kerry is scaling digital and AI initiatives across commercial, R&D, supply chain, manufacturing and business functions.

Latest results

In H1 2026 revenue was €3,336.4m, down 3.7% reported, with volume growth of 3.3%, pricing of -1.0% from input cost deflation and adverse translation currency of 4.8% from the weaker US$. EBITDA was €558.1m at a 16.7% margin (+60bps) and adjusted EPS rose 7.9% in constant currency to 214.1c. The Q3 2026 statement reported nine-month volume growth of 3.6%, stepping up to 4.1% in Q3, with pricing turning positive (+0.2%) and EBITDA margin up 50bps year to date. Kerry maintains FY2026 guidance of 6% to 10% constant currency adjusted EPS growth.

Investments and deals

Capacity and innovation centres
€301m of capex in 2025, including a Biotechnology Centre in Leipzig, enzyme capacity in Cork, coffee extraction in Pennsylvania and customer innovation centres in Dubai, South Jakarta and Frankfurt; 2026 investments include beverage taste capacity in North America, savoury taste in Mexico, proactive health in Spain and a taste footprint in Türkiye.
Bolt-on M&A
Bolt-ons of EUR 100 million-EUR 200 million per year in emerging markets and biotechnology (biotics and bioactives, enzymes, food protection and preservation).
Share buybacks
€500m of shares repurchased in 2025 and €172.9 million in H1 2026, with a further buyback of up to €300 million planned after the current programme.

Challenges and risks

Currency translation
The weaker US$ cut reported revenue by 4.8% in H1 2026 and is a 1-2% headwind to FY2026 EPS.
Weak European markets
Europe volumes fell 0.5% in FY2025, with Meals and Bakery still challenged in 2026.
Input cost inflation
The CFO expects 2027 to be inflationary, with dairy-based ingredients, some spices and natural oils rising, after deflation in H1 2026.
Geopolitical and macro uncertainty
Principal risks include trade wars, tariffs, currency volatility and consumer affordability challenges; China volumes were challenged in 2025.

What leadership says

“We see this as a structural market shift, it's primarily driven by actually increased consumer expectations.”

Edmond Scanlon, Chief Executive Officer · On renovation, H1 2026 results and 2030 targets call, 29 July 2026

“We are accelerating our investment in biotechnology innovation and very much doubling down”

Edmond Scanlon, Chief Executive Officer · Q3 2026 results call, 22 October 2026

“Having piloted and proven several initiatives across the organization, we are now scaling across commercial, R&D, supply chain, manufacturing, and business functions.”

Edmond Scanlon, Chief Executive Officer · On digital and AI, Q3 2026 results call, 22 October 2026

“we currently expect 2027 to be an inflationary year”

Marguerite Larkin, Chief Financial Officer · Q3 2026 results call, 22 October 2026

Where a supplier can help

Digital and AI rollout
Tied to the digital and AI priority and Accelerate 2.0's digital excellence workstream: Kerry is scaling AI across commercial, R&D, supply chain and manufacturing.
Footprint optimisation
Tied to Accelerate 2.0: plant consolidation in North America and Europe creates demand for automation, engineering and transition services.
Biotech R&D tooling
Tied to the biotechnology innovation priority and the rise of R&D spend to 5%-6% of revenue: lab equipment, fermentation and data tools.
Procurement and cost management
Tied to the input cost inflation challenge: sourcing analytics and hedging support for dairy, spices and natural oils.
Emerging-market expansion
Tied to new facilities in Egypt, Rwanda, Türkiye and the Middle East: construction, logistics and local distribution partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Kerry?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Kerry

What does Kerry Group do?

Kerry Group provides taste and nutrition ingredient solutions to food, beverage and pharma companies, co-creating products with customers in retail and foodservice.

What is Kerry Group's revenue?

FY2025 revenue from continuing operations was €6,758m with EBITDA of €1,208m. H1 2026 revenue was €3,336.4m.

How many employees does Kerry Group have?

19,000+ employees in 185+ locations and 50+ countries, with 119 manufacturing facilities in 34 countries.

Who leads Kerry Group?

Edmond Scanlon is CEO and Marguerite Larkin is CFO; the annual report names Fiona Dawson to take over from Tom Moran as Board Chair at the 2026 AGM.

What are Kerry Group's 2030 targets?

Volume growth of 3-5% a year, an EBITDA margin of 20-21% by 2030, HSD+ constant currency EPS growth, 85%+ cash conversion and 12-13% ROACE.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)